Abstract
Patient-derived xenografts (PDXs) are created by implanting human tumor tissue or cells into immunodeficent mice, and enable the study of tumor biology, biomarkers and response to therapy in vivo. This chapter describes a method for lung adenocarcinoma (LAC) PDX generation using subcutaneous implantation of tumor tissue and cell suspensions and incorporating the humanization of PDX models by reconstitution with human immune cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wang D, Pham NA, Tong J et al (2017) Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer 140(3):662–673
Jiang Y, Zhao J, Zhang Y et al (2018) Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study. J Transl Med 16(1):138
Fichtner I, Rolff J, Soong R et al (2018) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14(20):6456–6468
Kim M, Mun H, Sung CO et al (2019) Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun 10(1):1–15
Sachs N, Papaspyropoulos A, Zomer-van Ommen DD et al (2019) Long-term expanding human airway organoids for disease modeling. EMBO J 38(4):e100300
Reyal F, Guyader C, Decraene C et al (2012) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14(1):R11
Hidalgo M, Amant F, Biankin AV et al (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998–1013
Johnson JR, Hammond WG, Benfield JR et al (1995) Successful xenotransplantation of human lung cancer correlates with the metastatic phenotype. Ann Thorac Surg 60(1):32–37
Perez-Soler R, Kemp B, Wu QP et al (2000) Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6(12):4932–4938
Dong X, Guan J, English JC et al (2010) Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 16(5):1442–1451
Ilie M, Nunes M, Blot L et al (2015) Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. Cancer Med 4(2):201–211
Merk J, Rolff J, Becker M et al (2009) Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 36(3):454–459
Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388
Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394
Sundar R, Chénard-Poirier M, Collins DC et al (2017) Imprecision in the era of precision medicine in non-small cell lung cancer. Front Med 4:39
Zhang Y, Yao K, Shi C et al (2015) 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells. Oncotarget 6(42):44274–44288
Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833
Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288–2301
Hellmann MD, Paz-Ares L, Bernabe-caro R et al (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381(21):2020–2031
Ma Y, Zhang P, An G et al (2016) Induction of patient-derived xenograft formation and clinical significance of programmed cell death ligand 1 (PD-L1) in lung cancer patients. Med Sci Monit 22:4017–4025
Pearson T, Greiner DL, Shultz LD (2008) Creation of “humanized” mice to study human immunity. Curr Protoc Immunol 81(1):15–21
Bosma GC, Custer RP, Bosma MJ (1983) A severe combined immunodeficiency mutation in the mouse. Nature 301(5900):527–530
Ito M, Hiramatsu H, Kobayashi K et al (2002) NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175–3182
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Lundy, J., Jenkins, B.J., Saad, M.I. (2021). A Method for the Establishment of Human Lung Adenocarcinoma Patient-Derived Xenografts in Mice. In: Santiago-Cardona, P.G. (eds) Lung Cancer. Methods in Molecular Biology, vol 2279. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1278-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1278-1_13
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1277-4
Online ISBN: 978-1-0716-1278-1
eBook Packages: Springer Protocols